CVS Health (CVS) is having a "nice" start to 2025 as it posted "strong" Q1 results and cash flow generation, and ultimately lifted its annual outlook, Truist Securities said in a Thursday note.
The company's collaboration with Novo Nordisk (NVO) involving Wegovy weight loss drug looks to be an "attractive opportunity," analysts led by David MacDonald wrote.
Additionally, CVS intends to exit the Individual Exchange business next year in regions where it is an independent operator, as its management expects no "meaningful improvement" in the segment, the analysts said.
"Regarding utilization, trends remain elevated though are running broadly in-line with management expectations and the company called out signs of stabilization," the analysts said.
Truist Securities maintained its buy rating and $82 price target on CVS stock.
Shares of the company were down 1.7% in recent Friday trading.
Price: 68.26, Change: -1.20, Percent Change: -1.72
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。